Incyte (INCY) Stock Price
$72.11 0%
to add to portfolio
AI Score

-
Alternative
7 -
Fundamental
8 -
Technical
6
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Incyte, AI stock picks, stock alerts and much more.
INCY AI Stock Analysis
Financial Performance
Incyte's revenue has been growing consistently, with a reported increase of 9% from the previous quarter and 12.3% YoY to $1.1B. This growth is reflected in their gross profit as well, which stands at $1.1B, up by 10.6% QoQ and 11.5% YoY.
However, the operating income shows a significant decrease of -22% YoY but an impressive recovery QoQ with an increase of 130%. The EBITDA ratio for the last quarter was relatively low at 0.16 indicating lower profitability.
Stock Price
The stock price has shown positive trends recently with an increase of 2.9% over the last month and a substantial rise of around 12.4% YoY currently trading at $70.54 against its 200-day moving average of $63.98.
The RSI value stands at moderate level (48), suggesting that it is neither overbought nor oversold significantly while PE ratio stands high at around 783, reflecting potentially overvalued status compared to earnings.
Alternative Data Signals
Incyte's web traffic has seen a considerable uptick with visitors increasing by about 23% MoM and around 30% YoY to approximately ~52K per month which could indicate increased interest or engagement with Incyte’s products or services.
The number of job openings have decreased both MoM (-6%) and YoY (-17%), possibly indicating slowed expansion or cost saving efforts on part of Incyte.
Around half (59%) employees report having a neutral business outlook showing moderate confidence in the company's future.
Social media following has seen a modest increase with Twitter followers increasing by 0.6% and Facebook followers by around 6% over the last quarter, indicating steady brand recognition and engagement.
Conclusion
The overall analysis suggests that Incyte is showing signs of growth in terms of stock price and revenue, but there are concerns regarding profitability due to lower EBITDA ratio. The high PE ratio may also suggest overvaluation. However, increased web traffic and stable social media engagement could be promising signals for future performance. Thus, this analysis leans towards a cautiously optimistic or 'neutral' outlook for Incyte's stock.
Note: This AI Stock Analysis is based on data as of January 11. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Incyte (INCY) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Incyte (INCY), currently trading at $72.11, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About INCY

-
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
-
Symbol
INCY
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
14B
Similar Stocks
![]() |
Catalyst Pharmaceuticals CPRX |
$21.62 2% |
6 |
![]() |
Inovio Pharmaceuticals INO |
$2.24 0.9% |
2 |
![]() |
Moderna MRNA |
$35.53 5.3% |
4 |
![]() |
Anavex Life Sciences AVXL |
$8.35 3.8% |
6 |
![]() |
BridgeBio Pharma BBIO |
$36.85 0.1% |
6 |
News
INCY Alternative Data
Web Traffic
Incyte receives an estimated 58156 monthly visitors to incyte.com.
-
Web Traffic
58156
-
Change from Previous Month
11.8%
-
3 Month Change
37.9%
-
YoY Change
37.9%
News Mentions
Incyte was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
100%
-
1 Month Change
100%
-
3 Month Change
0%
Reddit Mentions
Incyte has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
Twitter Followers
Incyte has 6,471 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.3% over the last month.
-
Twitter Followers
6471
-
Daily Change
0%
-
1 Month Change
0.3%
-
3 Month Change
0.5%
-
YoY Change
0.5%
Facebook Engagement
Incyte has engaged 81 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
81
-
Daily Change
0%
-
1 Month Change
44.6%
-
3 Month Change
69.3%
-
YoY Change
69.3%
Youtube Subscribers
Incyte has 245 subscribers on its main Youtube channel, up by 1.7% over the last month.
-
Youtube Subscribers
245
-
Daily Change
0%
-
1 Month Change
1.7%
-
3 Month Change
3.4%
-
YoY Change
3.4%
LinkedIn Followers
103,044 are following Incyte on LinkedIn, up by 2.6% over the last month.
-
LinkedIn Followers
103044
-
Daily Change
0.1%
-
1 Month Change
2.6%
-
3 Month Change
8.2%
Job Postings
Incyte currenly has an estimated 141 open job postings, up by 83.1% over the last month.
-
Job Postings
141
-
Daily Change
0.7%
-
1 Month Change
83.1%
-
3 Month Change
161.1%
-
YoY Change
161.1%
LinkedIn Employees
According to LinkedIn, Incyte has 2,985 employees, up by 0.2% over the last month.
-
LinkedIn Employees
2985
-
Daily Change
0%
-
1 Month Change
0.2%
-
3 Month Change
1.6%
-
YoY Change
1.6%
Business Outlook
-
Business Outlook
59
-
Change from Previous Month
11.3%
-
3 Month Change
0%
-
YoY Change
0%
INCY Financials
INCY Key Metrics
-
Total Revenue
$1.1B
-
Net Income
$106.5M
-
Earnings per Share
$0.55
-
Free cash flow
$293.2M
-
EBITDA
$179.8M
-
EBITDA Ratio
0.15803
-
Total Assets
$5B
INCY 2-year Revenue & Income
INCY 2-year Free Cash Flow
INCY Technicals
INCY SMA
INCY RSI
FAQ
What's the current price of Incyte (INCY) Stock?
The price of an Incyte (INCY) share is $72.11.
What's the market cap of Incyte?
The current market cap of Incyte is 14B.
Should I buy or sell INCY?
Multiple alternative data signals suggest that Incyte stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is Incyte a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Incyte stock. The bullish indicators suggest that Incyte's growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy Incyte (INCY) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Incyte stock, given the bullish outlook.
What are some stocks similar to Incyte (INCY) that investors often compare it to?
Incyte (INCY) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Incyte's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Incyte's stock price to be around $78.21 in 2026. Starting from the current price of $72.11, this represents a 8.5% change in price, indicating a bullish outlook for the stock.
How to buy Incyte (INCY) Stock?
Incyte stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Incyte shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.